Rezafungin Acetate Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 200 mg
Reference Brands: Rezzayo (USA)
Category:
Anti-fungal
Rezafungin Acetate is available in Injection
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Rezafungin Acetate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Rezafungin Acetate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Rezafungin, marketed under the brand name Rezzayo by Melinta Therapeutics, is a next-generation echinocandin antifungal medication used for the treatment of invasive candidiasis, including candidemia. It is specifically indicated for adult patients in the United States who have limited or no alternative treatment options for these serious and potentially life-threatening fungal infections.
Rezafungin works by inhibiting the fungal enzyme β-(1,3)-D-glucan synthase, which is essential for the formation and maintenance of the fungal cell wall. Inhibition of this enzyme leads to cell wall instability and ultimately results in fungal cell death. The drug demonstrates potent activity against a broad range of Candida species, including strains that may be resistant to other antifungal therapies.
A key advantage of rezafungin is its extended half-life, which enables once-weekly intravenous dosing. This dosing schedule offers significant clinical and logistical benefits compared to daily echinocandin therapy, particularly for hospitalized or critically ill patients. Through its targeted mechanism of action and convenient dosing profile, Rezzayo represents an important advancement in the management of invasive fungal infections.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing